Ocular Therapeutix (OCUL)
(Real Time Quote from BATS)
$7.90 USD
-0.47 (-5.62%)
Updated Aug 8, 2024 03:52 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
OCUL 7.90 -0.47(-5.62%)
Will OCUL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OCUL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCUL
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
OCUL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
Other News for OCUL
Positive Financial and Clinical Trials Outlook Solidifies Buy Rating for Ocular Therapeutix
Ocular Therapeutix price target lowered by $1 at Baird, here's why
Positive Outlook for Ocular Therapeutix: Buy Rating Affirmed Amidst FDA Alignment and Promising Trial Progress
Ocular Therapeutix Inc (OCUL) Q2 2024 Earnings Call Transcript Highlights: Strong Cash Position ...
Buy Rating Justified by Ocular Therapeutix’s Rapid SOL-1 Trial Progress and Positive FDA Feedback on SOL-R